PHARMAC is supporting New Zealand’s first Pacific pharmacists' group to establish itself as a formal entity.
Funding cetuximab for patients with head and neck cancer will be a significant advance for treating this type of cancer in New Zealand, says PHARMAC Director of Operations Sarah Fitt.
Post-menopausal women with early breast cancer will soon be able to have funded zoledronic acid, to prevent the disease spreading into bones.
Achieving equity in medicines access is one of the bold goals PHARMAC has set itself to achieve by 2025.
PHARMAC is welcoming the presentation of results from the international SOLD trial, comparing short and long duration treatment with trastuzumab (Herceptin) for early HER 2-positive breast cancer.
PHARMAC is giving people a choice of four funded CareSens meters, including a dual meter that measures both blood glucose and ketones.
Stuart McLauchlan Chair PHARMAC today announced that Sarah Fitt, Director of Operations will be appointed as PHARMAC's new Chief Executive effective from Saturday 6 January 2018
PHARMAC has announced today that its Chief Executive, Steffan Crausaz, will be stepping down to take up a new role in the private-sector in New Zealand.
Over 600,000 New Zealanders will be able to avoid the often painful and debilitating shingles infection following PHARMAC’s decision to fully fund the shingles vaccine.
Hundreds of people with diabetes are set to benefit from the funding of a new treatment that will help prevent blindness.
From 1 November 2017 dexamethasone implants (brand name Ozurdex) will be funded for eligible people with diabetic macular oedema (DMO), a serious complication of type 1 and type 2 diabetes that can cause blindness if untreated.
Article based on an interview with Prof. Keith Petrie about generic medicines and how prescribers’ own views about generic medicines can affect patient outcomes.
Thousands of children a year are set to avoid chickenpox infection, with flow-on benefits to families and the wider health system, after the varicella vaccine which prevents chickenpox is funded from 1 July 2017.
PHARMAC has announced the funding of five new treatments and wider use of over 30 existing treatments, which are set to benefit many New Zealanders from 1 July 2017.
PHARMAC is pleased to confirm a long-term supply for metoprolol succinate. From 1 March 2018, AstraZeneca will be the sole-supplier of metoprolol succinate in New Zealand, with its brand Betaloc-CR.
A series of 38 funding proposals across the breadth and scope of PHARMAC’s work has been released for public feedback.
A new strategy for Pacific health provides an exciting opportunity to improve the health of Pacific people in New Zealand, says PHARMAC Chief Executive Steffan Crausaz.
Twenty years after it was first tendered, new funding decisions for paracetamol are still making a difference.
Funded influenza vaccinations will be available from more community pharmacies this year.
Researchers from Auckland and Otago Universities are the first recipients of new grants from PHARMAC and the Health Research Council of New Zealand (HRC).
PHARMAC has received a funding application for sanitary pads and tampons.